Open an account

Alpha Tau Medical

DRTS · NASDAQ

$13.16+$0.26 (+2.02%)TodayMarket closed ·
Prev close $12.90

DRTS analyst rating

BuyConsensus of 5 analysts over the last 12 months. 80% rate it a buy.
  • Strong buy0
  • Buy4
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 7 analysts

Average $18.16 (+38.0% upside)

Low
$8.08
Now
$13.16
High
$31.50

Upgrades and downgrades

The latest rating actions, newest first

DRTS analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Oct 20, 2026MaintainsBuy
BarclaysSep 3, 2026MaintainsOverweight
HC Wainwright & Co.Aug 11, 2026MaintainsBuy
HC Wainwright & Co.Jul 22, 2026MaintainsBuy
HC Wainwright & Co.Jul 16, 2026MaintainsBuy
HC Wainwright & Co.Jun 4, 2026MaintainsBuy
BarclaysJun 4, 2026MaintainsOverweight
HC Wainwright & Co.Jun 2, 2026MaintainsBuy
BarclaysMay 28, 2026InitiatesOverweight
HC Wainwright & Co.May 20, 2026MaintainsBuy

The case for and against

Updated Oct 21, 2026

Bull case

Alpha Tau Medical is viewed positively because its Alpha DaRT platform is generating meaningful clinical proof-of-concept across multiple difficult solid tumors, including 100% ORR and 18.2 months of median overall survival in HNSCC when combined with pembrolizumab, while also showing no serious Alpha DaRT-associated adverse events. The company also has several near-term catalysts in 2H26 and late 2026 or early 2027, including REGAIN, IMPACT, and ReSTART updates, plus a first U.S. prostate cancer patient treated, which could broaden regulatory and commercial optionality. Despite a 2Q26 net loss of $45.8M, the stock’s fundamentals are supported by advancing pivotal and pilot studies, clearance to expand REGAIN enrollment, and a potential PMA pathway under Breakthrough Device designation.

Bear case

Alpha Tau Medical is a clinical-stage oncology company whose valuation depends heavily on Alpha DaRT, yet that asset is still subject to major clinical, regulatory, and commercialization uncertainty across key indications such as SCC and GBM. The cited DCF framework relies on aggressive assumptions, including a 15% discount rate, 2% terminal growth, and approval probabilities of 75% for SCC, 60% for GBM, and 100% for head & neck cancer in Japan, which leaves meaningful downside if development slips or adoption is weaker than expected. With only $104.8M cash in one scenario and $80.2M in another, 92.4M or 90.2M shares outstanding, and explicit dilution risk, the downside outlook reflects a business with limited financial cushion and high execution risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.